Citius pharmaceuticals, inc. secures $2.4 million through new jersey economic development program

Net operating losses converted into non-dilutive capital cranford, n.j. , march 7, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced that the company has received $2.4 million in non-dilutive capital through new jersey's technology business tax certificate transfer program, more commonly known as the net operating loss (nol) program, funded through the new jersey economic development authority (njeda).
CTXR Ratings Summary
CTXR Quant Ranking